Cancer Discovery Could Help Revitalize Non-Toxic Treatment


Researchers at the University of Virginia have published a new study that could reinvigorate once-promising treatments that help fight solid cancer tumors, the university announced Monday. cancer, was successful in laboratory tests but failed in human trials. Lead researcher Jogender Tushir-Singh, from the Department of Biochemistry and Molecular Genetics at the UVA School of Medicine, says the new findings could help restart human trials after new success in laboratory models. Until now, researchers and protein engineers around the world, including our research group, have focused on antibodies targeting tumor cell killing receptors by overloading and over-activating in the fight against cancer, “said Tushir-Singh.” Here at UVA, he took a comprehensive approach to harnessing the power of the immune system to create potentially clinically effective, dual-specificity cancer therapies for solid tumors. “

“Our findings also have significant potential to further improve the clinical efficacy of currently FDA-approved anti-PD-L1 antibodies in solid tumors, particularly those approved for fatal triple-negative breast cancer,” added Tushir-Singh. . Scientists first developed an approach that selectively uses antibodies to attack the surface of cancer cells called death receptor-5 (DR5). The treatment has been successful in clinical trials in the past, effectively shrinking the tumor in animal trials. However, when the treatment reached human clinical trials, “these antibodies failed to improve patient survival.” Tushir-Singh and her team found that “anti-DR5 antibody approaches inadvertently trigger biological processes that suppress the body’s immune response.” The university explained in a statement, allowing cancer cells to avoid treatment and continue to grow.

The research shares findings that could restore the efficacy of the treatment by fighting the biological process, which has so far been shown to be successful in shrinking tumors and improving survival in laboratory mice. “We would like to see these strategies in clinical trials, which we strongly believe have great potential in solid tumors,” said Tushir-Singh. “Our findings are extraordinary: along with the translational impact, our work also explains, after more than 60 years of research in the field, why most approaches targeting apoptosis [cell death] They haven’t done well in clinical trials and ultimately develop resistance to therapies. “



Source link